within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J02A_AntimycoticsForSystemicUse.J02AC04_Posaconazole;

model Posaconazole
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.54,
    Cl = 2.0833333333333334e-06,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.236,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.000585,
    Tlag = 900);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Posaconazole</td></tr><tr><td>ATC code:</td><td>J02AC04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>236</td><td>L</td></tr>
    <tr><td>clearance:</td><td>7.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Posaconazole is a triazole antifungal agent approved for the prevention and treatment of invasive fungal infections caused by Aspergillus and Candida species in immunocompromised patients. It is used both for prophylaxis in patients at high risk for fungal infections and for treatment of ongoing invasive infections. Approved by FDA and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers (median age 26, range 18–45), single-dose pharmacokinetics of oral posaconazole suspension following 400 mg dose in the fed state.</p><h4>References</h4><ol><li><p>Chen, L, et al., &amp; Brüggemann, RJM (2020). Pharmacokinetics and Pharmacodynamics of Posaconazole. <i>Drugs</i> 80(7) 671–695. DOI:<a href=\"https://doi.org/10.1007/s40265-020-01306-y\">10.1007/s40265-020-01306-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32323222/\">https://pubmed.ncbi.nlm.nih.gov/32323222</a></p></li><li><p>Selby, PR, et al., &amp; Roberts, JA (2024). Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients. <i>The Journal of antimicrobial chemotherapy</i> 79(3) 567–577. DOI:<a href=\"https://doi.org/10.1093/jac/dkae006\">10.1093/jac/dkae006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38217845/\">https://pubmed.ncbi.nlm.nih.gov/38217845</a></p></li><li><p>Ding, Q, et al., &amp; Pei, Q (2022). A Review of Population Pharmacokinetic Models of Posaconazole. <i>Drug design, development and therapy</i> 16 3691–3709. DOI:<a href=\"https://doi.org/10.2147/DDDT.S384637\">10.2147/DDDT.S384637</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36277600/\">https://pubmed.ncbi.nlm.nih.gov/36277600</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J02AC04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Posaconazole;
